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in cancer: the strange case of LKB1/PAR-4
Johanna I. Partanen†, Topi A. Tervonen† and Juha Klefstro¨m
Cancer Cell Circuitry Laboratory, Translational Cancer Biology Research Program and Institute of Biomedicine,
University of Helsinki, Biomedicum Helsinki, Rm B507b, PO Box 63, Haartmaninkatu 8, 00014 Helsinki, Finland
The PAR clan of polarity regulating genes was initially discovered in a
genetic screen searching for genes involved in asymmetric cell divisions in
the Caenorhabditis elegans embryo. Today, investigations in worms, flies and
mammals have established PAR proteins as conserved and fundamental
regulators of animal cell polarization in a broad range of biological phenomena
requiring cellular asymmetries. The human homologue of invertebrate PAR-4,
a serine–threonine kinase LKB1/STK11, has caught attention as a gene behind
Peutz–Jeghers polyposis syndrome and as a bona fide tumour suppressor
gene commonly mutated in sporadic cancer. LKB1 functions as a master reg-
ulator of AMP-activated protein kinase (AMPK) and 12 other kinases referred
to as the AMPK-related kinases, including four human homologues of PAR-1.
The role of LKB1 as part of the energy sensing LKB1-AMPKmodule has been
intensively studied, whereas the polarity function of LKB1, in the context of
homoeostasis or cancer, has gained less attention. Here, we focus on the
PAR-4 identity of LKB1, discussing the weight of evidence indicating a role
for LKB1 in regulation of cell polarity and epithelial integrity across species
and highlight recent investigations providing new insight into the old ques-
tion: does the PAR-4 identity of LKB1 matter in cancer?1. Introduction
The famous narrative from the Scottish author Robert Louis Stevenson, The
Strange Case of Dr Jekyll and Mr Hyde, keeps inspiring not only those fascinated
by psychiatric split personality disorder but also cell biologists working on
multi-functional proteins. In this sense, the tumour suppressor protein LKB1/
PAR-4 is a strange case. The LKB1 identity of this kinase protein, also known
as serine/threonine kinase 11 (STK11), has been associated with upstream acti-
vation of the two isoforms of AMP-activated protein kinase (AMPK) and 12
AMPK-related kinases (ARKs). Doubtless, LKB1 is a key regulator of cell
metabolism. However, LKB1/STK11 has yet another identity because the
protein is a human homologue of PAR-4, a member of a PAR clan of proteins
involved in regulation of cell polarity in worms, flies and mammals. Which,
among the multiple identities of a single protein LKB1/STK11/PAR-4, is
then Dr Henry Jekyll and which is the evil Mr Edward Hyde? The answer is
obvious: none is Mr Hyde because cells do not express evil proteins. However,
it appears that the bad nature of Mr Hyde surfaces on the pathways that suffer
from loss of LKB1. Inheriting a mutated copy of the LKB1 gene predisposes to
autosomal-dominant Peutz–Jeghers polyposis syndrome (PJS) and multiple
cancers. LKB1 is also mutated in a variety of sporadic cancers. When cells
lose LKB1, they also lose a mechanism to activate AMPK. Without AMPK
activity, cells are not capable of controlling the mammalian target-of-rapamycin
(mTOR) pathway, and consequently cells lose their grip on growth control and
proliferation. This chapter about LKB1 is almost like something from the
Stevenson story—Dr Jekyll is not inherently a good person but he is not
acting like Mr Hyde because he is able to repress impulses, which feed the
savage behaviour of Mr Hyde. How does the loss of PAR-4 identity become vis-
ible in tumour-prone cells that have lost LKB1? Investigations in flies and
mammals have shown that cells without PAR-4 (LKB1) activity suffer from
an inability to maintain apico-basal polarity and to sustain integrity of cell–cell
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2junctions, including apical junctions. Damage at apical tight
junctions in these cells may be a deed of Mr Hyde, because
loss of cell cohesion promotes invasion of the cancer cells
into neighbouring tissues. However, we posit in this
review that one witnesses the true savageness of Mr Hyde
in a ferocious assault that PAR-4-derepressed pathways
launch against the basal side of the cells. The attack shatters
the basement membrane using a transmembrane serine pro-
tease called Hepsin—akin to the heavy cane that Mr Hyde
uses to beat his first victim to death. Basement membrane
is the last line that cancer cells have to cross before they
can invade connective tissue.
We first introduce here a few basic concepts of cell
polarity and epithelial integrity, discussing how impaired
control of these mechanisms may promote tumorigenesis.
Thereafter, we focus on LKB1, discussing the relevance of
the PAR-4 identity of LKB1 in polarity regulation and cancer.8:201301112. Loss of epithelial polarity in cancer:
an epiphenomenon or a cause?
Epithelial tissues vary in form and function, but the basic
principle of apico-basal polarity is similar in different tissues.
In polarized epithelial cells, the apical surface is oriented
towards the lumen or external environment. This side of the
epithelial cell, which often has membrane protrusions (micro-
villi), takes care of the absorption, exchange and secretion of
molecules and macromolecules [1]. Lateral surfaces of the
epithelial cells contact adjacent cells via specialized cell–cell
junctions, namely tight junctions, adhesion junctions and
desmosomes. On the opposite side of the apical membrane is
the basal surface,which anchors cells to a basementmembrane.
Basement membrane is a thin (about 100 nm), dense sheet
composed of a meshwork of insoluble molecules including
laminin polymers, a cross-linked network of collagen IV fibrils,
proteoglycans and glycoproteins [2,3].
(a) Epithelial cell polarity: frame and function
Polarized membranes and cytosolic molecular asymmetries
are fundamentally important for epithelial cells to function
as a multi-cellular organized tissue. The molecular asymme-
tries guide directional exocytosis and secretion of digestive
enzymes from pancreas, milk from mammary epithelium
and vectorial transfer of nutrients across the gut epithelium
to blood [1]. Furthermore, extension of epithelial monolayers
requires that cell divisions occur in the plane of the sheet
and many key cell polarity proteins are involved in determin-
ing alignment of the mitotic spindle so that it is perpendicular
to the axis of apico-basal polarity [4–6]. In addition to many
proteins, lipids are also asymmetrically distributed in polar-
ized cells [1]. In particular, the asymmetric distribution of
phosphatidylinositol phosphates Ptd(4,5)P2 (PIP2) and
Ptd(3,4,5)P3 (PIP3) along the apico-basal axis, observed in sev-
eral cell types, has been attributed to the differential activities
of PTEN phosphatases and PtdIns3-kinases (PI3K) on the
apical and basolateral sides of cells [1,7,8]. Developing (pri-
mordial) adhesion junctions, tight junctions, desmosomes
and basal cell surface–basement membrane contacts provide
landmarks and orientation cues for development of apico-
basal cell polarity [1,9]. Tight junctions maintain the polarized
status of membrane domains by physically restricting lateraldiffusion of integral membrane proteins. Also, key cadherins
of adhesion junctions and desmosomes, E-cadherin and des-
mocollin, are necessary for proper formation of cell polarity
and organization of epithelial structures [10]. Furthermore,
there is evidence indicating that hemidesmosomes, which are
structures attaching the basal surface of the cells to the under-
lying basement membrane at irregular intervals, are important
for development of polarized epithelial architecture [11]. At
the basal side of the cells, interference of b1-integrin contact
with laminin can even invert the apico-basal polarity so that
the apical surface becomes oriented towards the matrix [12].
The vesicular trafficking pathways, which are often guided
by distinct cytoskeletal tracks, are important cellular machi-
neries for maintenance of polarity as they direct and recycle
plasma membrane proteins specifically to the apical mem-
brane and basement membrane [9,13,14]. For example,
synthesis of functionally active basement membrane requires
both polarized localization of plasma membrane proteins,
for example integrins, and polarized secretion of basement
membrane proteins, for example laminins [3,15].
In Drosophila and mammals, the apical identity of apico-
basally polarized cells is maintained and regulated by two
conserved polarity complexes (named according to gene
names), the CRB/PALS1/PATJ (Crb) complex and the
PAR3/PAR6/aPKC (Par) complex. On basolateral sides of
the cells, a module of Scrib, Dlg and Lgl proteins controls
the basolateral identity [16]. Scrib, Dlg and Lgl physically
interact with each other in Drosophila epithelial cells, forming
a Scrib complex, whereas in mammalian cells, the nature of
these interactions is less clear. The core molecular machinery
that generates cellular asymmetry is conserved from worms
to mammals. The main components of the machinery are six
(or five depending on species) functionally, but not structu-
rally, related PAR (for ‘partitioning defective’) proteins [17].
The core set of PAR proteins, which is discussed in §3, along
with a limited number of other proteins such as aPKC and
CDC42, is involved in a broad range of phenomena requiring
cellular polarization, such as apico-basal polarity, neurite
extension, cellular migration and asymmetric cell division.(b) Epithelial cell polarity: collapse in cancer
Cancer progression from benign tumour (local mass of cells)
to invasive and metastatic cancer features loss of all afore-
mentioned characteristics of polarized epithelial cells.
Indeed, loss of organized epithelial structure, loss of cell
polarity and loss of basement membrane attachment are
among the key diagnostic criteria that differentiate benign
tumours from life-threatening malignant cancers. One could
envision that collapse of the polarity system benefits the pro-
cess of cancer progression in many ways (figure 1). For
example, erratic alignment of the mitotic spindle could
enable efficient expansion of a cell mass in every direction,
thus promoting hyperplasia. Out-of-alignment mitotic
spindle may also increase aneuploidy [5,23]. Altered cell
adhesion and extracellular matrix-dependent signalling
mechanisms may make cells more migratory [24], loss of
lipid asymmetry may deregulate spatial PI3K signalling
and any cell-intrinsic (e.g. loss of cues for directional
secretion) or -extrinsic mechanism harming basal polarity
could lead to deterioration of basement membrane,
thus paving the way to invasion and metastasis [24,25].
Thus, in general, the aforementioned qualities would
organized epithelial structure 
tumour progression
loss of epithelial integrity
increased
cell proliferation
loss of
cell polarity
loss of/altered
junctional complexes
deterioration
of basement membrane sensitivity to
apoptosis
increased
migration
Figure 1. Loss of epithelial integrity—a hallmark of all advanced cancers. A schematic of cellular level changes, which typify disintegration of epithelial structure
during tumour progression. Partial or complete loss of basement membrane (BM) is a defining diagnostic marker to distinguish the in situ type of carcinoma from
invasive carcinoma [18]. Loss of cell– cell junctions, for example via loss of E-cadherin, is a common feature associating with the epithelial–mesenchymal transition
[19,20]. Junctional complexes are also altered so that adhesive cell– cell junctions are loosened and migratory focal adhesions increased [19]. Loss of epithelial cell
polarity associates with deterioration of cell junctions and basement membrane, as discussed in this review, which enhances the proliferative potential and migratory
capacity of epithelial cells [21]. However, the cell polarity machinery cannot be completely demolished in cancer, because the core polarity machinery is necessary
not only for apico-basal polarity but also for cell migration [22]. Thus, evolving cancers may need to carefully select polarity targets so as to acquire benefits from
loss of apico-basal polarity but not to compromise ability to proliferate or migrate.
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3benefit arising tumours by cutting off cell structures, which
stabilize organized epithelial structure (cell–cell adhesions,
basement membrane), and endowing cells with new mig-
ratory capacities to move out of epithelial organizations and
into the stroma.
The polarized phenotype of epithelial cells is lost when a
tumour progresses towards malignancy, but it is still unclear
whether there are specific and prevalent genetic mutations
that contribute to tumour progression because they disrupt
epithelial cell polarity. So far, experiments in Drosophila pro-
vide the strongest evidence for a causal role of polarity
genes in tumour progression. The genes of the Scrib complex
form the core of Drosophila neoplastic tumour suppressor
genes (nTSGs) and, beyond nTSGs, inactivation of almost
any core gene of the polarity machinery, for example bazooka
(equivalent of human PAR3), stardust (similar to human
PALS1) and cdc42, dramatically promotes metastatic
behaviour of Ras or Raf-initiated tumours [16,26,27].
However, these findings in Drosophila may not directly
translate into human cancers, because many recently pub-
lished reports cataloguing the most frequently mutated genesacross thousands of human cancer genomes do not feature
polarity genes at the top of the lists. Our own investigation to
estimate the frequency of somatic mutations in polarity
genes, several years ago, suggested that these mutations are
indeed rare [21]. The rarity of mutations in core polarity
genes, however, does not mean that cell polarity would be an
irrelevant concept in cancer. In mammals, genetic redundancy
efficiently buffers against deleterious effects of single-gene
mutations, and there are commonly multiple homologues cor-
responding to prototypic Drosophila polarity genes [28]. This
means that, in mammals, tumour microevolution could prefer-
entially single out non-redundant polarity genes (rather than
the most typical) as targets for polarity-damaging mutations.
It is also worth noting that recent focused screens on cancer
cell lines for small intragenic deletions have identified hitherto
missed mutations in polarity genes, for example in PAR3,
paving the way for more precise analysis of polarity-gene
mutations in heterogenous primary tumour material [29].
Further evidence supporting the role of polarity genes as
potential tumour suppressor genes comes from the findings
that several core polarity genes, for example Dlg and Scrib,
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4are targeted for degradation by oncogenic human papilloma-
viruses [30]. Finally, in mouse models of human cancer, like
in Drosophila models of tumour progression, a cell polarity
gene deficiency (LKB1/PAR4, SCRIB, PAR3) can dramatically
promote tumorigenesis in tissues engineered to express a
dominantly acting oncogene, such as Myc or Ras [31–34].
The role of core polarity genes and surrounding regulat-
ory networks in cancer has been recently comprehensively
covered in many reviews. This emerging field of research
continues to inspire investigators as it holds promise for
identifying novel, fundamentally important pathways contri-
buting to tumour progression and invasion as well as new
therapies to fight cancer [7,9,34–36]. This review focuses on
liver kinase B1, serine–threonine kinase 11 (LKB1/STK11),
which is a human homologue of PAR-4. LKB1 has the stron-
gest link to cancer among the PAR proteins but it is also a
multi-functional protein with a number of other functions,
besides polarity regulation. 201301113. The LKB1 tumour suppressor gene:
PAR-4 and more
The LKB1 gene is the only human homologue of Caenorhabditis
elegans par-4 and Drosophila lkb1, encoding a serine–threonine
kinase with multiple functions in regulation of cell polarity,
metabolism and cell growth [37–39]. LKB1 is known as the
critical upstream kinase required for the activation of AMPK,
which is a cellular energy sensor and central regulator of
cell metabolism. The LKB1-AMPK module also operates via
the mTOR pathway to regulate cell growth [38]. These aspects
of LKB1 signalling and links of the pathways to cancer have
been covered in a number of recent reviews [37–39]. Below,
we review the incidence of LKB1 mutations in cancer and dis-
cuss the PAR-4 identity of LKB1, illuminating functions and
signalling of LKB1 in the context of physiological regulation
of cell polarity and epithelial tissue integrity.
(a) LKB1 in hereditary and sporadic tumours
Germline mutations in tumour suppressor LKB1 lead to
autosomal-dominant PJS, characterized by benign hamarto-
matous polyps occurring throughout the gastrointestinal tract
[40–42]. Patients with PJS also have a significantly increased
risk of developing cancer, for example, in the gastrointestinal
tract, pancreas, breast and ovaries [43–45].
Different types of sporadic cancers also harbour soma-
tic mutations in the LKB1 genes. Most frequently, LKB1
mutations have been found in non-small cell lung carcinoma.
In this cancer type, more than 30% of the cases have somatic
and homozygous inactivating mutations in LKB1 [46,47].
Somatic LKB1 mutations are also common in cervical
cancer, found in about 20% of cases [48]. In addition, LKB1
mutations have been observed in melanomas and cancers
of the pancreas, liver, breast and endometrium, although at
reduced frequency [49–53]. Reduced or missing expression
of Lkb1 has been reported in a range of cancers, including
endometrial, pancreatic and breast cancer [49,54–56]. In
breast cancer, LKB1 mutations appear to be rare, but loss
of expression is common based on the results from tissue
microarrays and Western blot analysis of tumours [32,54].
Loss of LKB1 expression has been attributed to epigenetic
silencing mechanisms, including promoter hypermethylationin breast cancer, and there is also some evidence that reduced
LKB1 levels correlate with poor prognosis in these cancers
[54,57,58]. In melanoma, posttranslational inactivation mech-
anisms may target LKB1 because mutated B-RAF leads to
phosphorylation of LKB1, which inhibits it from activating
downstream targets [59].(b) LKB1 as a polarity protein PAR-4
The PAR (partitioning defective) set of polarity regulating
proteins was initially found through a screen searching for
mutants that disrupt the first asymmetric cell divisions in
the C. elegans embryo [60]. PAR-4, the C. elegans homologue
of LKB1, was among the six PAR genes found necessary
for cytoplasmic partitioning and asymmetric cell division in
the worm zygote (figure 2). Subsequent studies have exposed
PAR proteins as fundamental regulators of cell polarization
in diverse animals and different contexts of polarity [17].
The core PAR proteins are a diverse group of proteins:
PAR-1 and PAR-4 encode serine–threonine kinases, PAR-5
belongs to the 14-3-3 family of proteins, which are recruited
to phosphorylate serines and threonines. PAR-3 and PAR-6
contain PDZ domains, which are signalling and protein inter-
action scaffolds, and PAR-2 has a RING finger domain that
may be used in the ubiquitination pathway. PAR proteins
1, 2, 3 and 6 acquire asymmetric localization patterns
during the development of cell polarization in C. elegans,
whereas PAR-4 remains symmetrically localized in cortex
and cytoplasm during the process [17]. Interestingly from
the LKB1 perspective, epistatic analyses have demonstrated
that PAR-4 is essential for establishment of PAR-3/PAR-6
asymmetry, suggesting that PAR-4 may master-regulate the
asymmetric segregation of other PAR family proteins [40,61].
In Drosophila (figure 2), PAR-4/lkb1 is required for the for-
mation of early anterio-posterior polarity in oocytes and
epithelial apico-basal polarity in follicle cells [62]. In adult
Drosophila retinal cells, inactivation of lkb1 also leads to dis-
ruption of polarity and further disarrangement of cell–cell
junctions and membrane domains [63]. The signalling circui-
tries, which in flies may operate downstream of lkb1 in
epithelial polarity regulation, are discussed below.
In mammalian cells (figure 2), construction of a STRAD
adaptor protein-mediated system to ectopically activate LKB1
by Baas et al. [64] led to a surprising finding that activation of
LKB1 is sufficient to polarize single, isolated intestinal epithelial
cells in culture—a finding that challenged current views of the
importance of cell–cell contacts in the process of polarization.
Subsequent descriptive and functional studies have pictured
LKB1 as a cell-polarity-linked protein in various contexts of
mammalian tissue asymmetries. For example, LKB1 has been
implicated in polarization of mouse oocytes [65]. Furthermore,
LKB1 is required for axon specification during polarization of
cortical neurons [66,67] and it participates in the formation of
Sertoli cell polarity and testicular junctions [68].
Recent studies fromour laboratory have also suggested that
LKB1 is crucial for the integrity of mammary epithelial tissue
[32,69]. A detailed analysis of three-dimensional cultures of
primary mouse mammary epithelial cells (MMECs), rendered
LKB1 deficient by adenoviral Cre infection, shows that loss
of LKB1 disorganizes the normally rounded phenotype of
acinus-like structures. Characteristic of LKB1-deficient struc-
tures is lateralized or completely mislocalized expression of
apical polarity markers. In an electron microscopic analysis,
PAR-4/
LKB1
PAR-1
mammalian epithelial cells
mammalian neuronsDrosophila melanogaster
Caenorhabditis elegans
— asymmetric division of 
     embryonic cells
— polarization of single intestinal epithelial cells
— polarization of oocytes
— polarization of pancreatic acini
— anterio-posterior polarization of oocyte
— polarization of follicular epithelial cells
— polarization of retinal cells
— metabolic control of cell polarity
— initiation of neuronal polarization 
— polarized migration
— polarization of mammary epithelial cells
— polarization of Sertoli cells
BRSK-1
BRSK-2
AMPK
Figure 2. LKB1/PAR-4 in regulation of cell polarity. LKB1 functions as a PAR-4 cell polarity gene in C. elegans, Drosophila and mammalian epithelial and neuronal
cells. Highlighted are suggested downstream targets, through which LKB1 may regulate cell polarity in different systems.
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5the LKB1-deficient three-dimensional structures show multi-
ple abnormalities in desmosomes and tight junctions as well
as deteriorated basement membrane. A selective deletion of
LKB1 in the adult mammary gland, obtained by crossing
mice with floxed LKB1 alleles with mice harbouring a lacto-
genic hormone-inducible WAP-Cre construct leads to many
similar phenotypes observed in the in vitro three-dimensional
cultures. The LKB1-deficient mammary ductal and alveolar
structures express a disorganized pattern of apical markers
and incomplete basement membrane as well as displaying
enhanced branching of the ducts [32]. However, inactivation
of LKB1 may lead to strikingly different phenotypes in
different epithelial tissues as discussed next.
(c) LKB1 and epithelial tissue morphogenesis
The basic architecture of epithelial tubes in all branching
organs, for example, kidney, mammary gland, lung and
blood vessels, is a polarized epithelium that apically faces a cen-
tral luminal space and basally contacts basement membrane
[70]. The mechanisms of branching are complex and vary
between different tissue types, but the main underpinnings of
the branching process are coordinated actions between prolifer-
ation, apico-basal polarity and epithelial motility machineries.
Several investigations have also highlighted the role of base-
ment membrane as a scaffold providing cues for reorientation
of polarity during the branching process as well as incomplete
basement membrane coverage at branching points as an
element regulating branching morphogenesis [70].
Recent investigations have coupledLKB1 to branchingmor-
phogenesis in two different organs—lung and the mammary
gland. The study of Lo et al. [71], using an ATP-binding
pocketmodified formof LKB1 that confers sensitivity to specific
inhibition by a small molecule ATP analogue, shows that
inactivation of the modified LKB1 inhibits branching morpho-
genesis of embryonic lung tissue in an ex vivo explant culture.
The branching defect was rescued by activation of AMPK,
suggesting a role for the LKB1-AMPK pathway in the branch-
ing process. The same study also shows that the phenotypiceffects resulting from inactivation of LKB1 are tissue- and
context-specific. In pancreatic tissue, chemical inactivation of
LKB1 results in development of cystic structures bymechanisms
not involving defective AMPK signalling.
In the study of Partanen et al., conditional deletion of
LKB1 genes, ex vivo, in three-dimensional organoids and,
in vivo, in the mammary gland, leads to hyperbranching of
the mammary ducts. In the mammary gland, loss of LKB1
simultaneously leads to defects in cell polarity, cell junctions
and basement membranes [32]. In the study of Lo et al. [71],
polarity defects were not observed in embryonic lung tissue
after inactivation of LKB1. Therefore, it is possible that the
hyperbranching phenotype results from loss of polarity and
incomplete basement membrane coverage, and in tissues
spared from these defects, LKB1 loss may have other, even
opposite effects.(d) LKB1/PAR-4 signalling pathways in
epithelial polarity
The kinase activity of LKB1 in mammalian cells requires the
formation of a heterotrimeric complex consisting of LKB1,
pseudokinase Ste20-related adaptor protein (STRAD) and a
scaffold protein, for example mouse protein 25 (MO25)
[72,73]. Binding to STRAD and MO25 renders LKB1 active
and furthermore, regulates stability and localization of LKB1
protein [73,74]. LKB1 functions as a master regulator of the
two isoforms of AMPK (AMPK-a1 and AMPK-a2) and 12
other kinases referred to as the ARKs [75–78]. All LKB1-regu-
lated downstream kinases, AMPK and ARKs, require LKB1-
dependent phosphorylation in the threonine 172 (T172) (or
equivalent residue) that resides in the activation loop to
become active. The AMPK and ARK serine–threonine kinases
belong to a small subfamily of calcium/calmodulin-dependent
protein kinases comprising AMPK-a1 and AMPK-a2, four
MARK/PAR-1 kinases (MARK1-4), the AMPK-related kinase
5 (ARK5, NUAK1), the SNF/AMPK-related kinase (SNARK,
NUAK2), two Brain-specific kinases (BRSK1 and 2), three
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6salt-induced kinases or SIKs (SIK1/SIK, SIK2/QIK and SIK3/
QSK) and the Snf-related serine/threonine kinase (SNRK) [76].
Among the LKB1 downstream kinases, AMPKs, MARK/
PAR-1 kinases and BRSK1 and 2 have been linked to regulation
of cell polarity in a context-dependent manner (figure 2). Find-
ings inDrosophila have suggested that LKB1may use AMPK to
signal cell polarity [79]. In Drosophila follicular epithelial cells,
ampk-a null mutants exhibit normal epithelial polarity in a
nutrient-rich environment but in culture media deprived of
sugars, conditions where AMPK normally is maximally
active, apico-basal cell polarity of these cells is disrupted.
Also lkb1 mutants show similar energy-starvation-dependent
polarity defects, which can be rescued by a constitutively
active AMPK transgene [79]. Another study has shown that
downstream of the ampk-a mutation, a constitutively active
form of a protein non-muscle myosin regulatory light chain
(MRLC or MLC2) rescues the polarity defects of ampk-a
mutant cells [80]. These investigations altogether suggest that
at least in flies, the LKB1-AMPK-MRLC module regulates cell
polarity in a mode that is responsive to cues from cellular
energy status. In mammals, branching defects in embryonic
lung tissue, caused by LKB1 inactivation, can be rescued via
ectopic activation of AMPK [71]. In cultured mammalian
cells, AMPK has also been shown to play a role in cell polarity
and formation of tight junctions [81,82].
Mammalian microtubule-associated protein (MAP)/
microtubule affinity-regulating kinases (MARKs) are homol-
ogues of C. elegans PAR-1, which was identified in the same
C. elegans partitioning defective screen as LKB1/PAR-4 [60].
PAR-1 serine/threonine kinase regulates other PAR proteins
to establish cell polarity. For instance, in Drosophila, PAR-1
phosphorylates PAR-3 to retain it in the apical pole of the
oocyte [83]. In mammals, MARK2 (PAR1b) has been impli-
cated as a downstream effector of LKB1 in regulation of
apico-basal polarity of pancreatic acinar cells in vivo [84].
Recently, it was found that MARK2 physically associates
with a RhoA-specific guanine nucleotide exchange factor,
influencing RhoA activity and the actin cytoskeleton. This
interaction could couple PAR-1-dependent polarity regulation
to cellmovement [85]. The virulence factor CagA inHelicobacter
pylori cagA-positive strains interacts withMARKs/PAR1 caus-
ing junctional and polarity defects. It is believed that this
interaction leads to the disorganization of epithelial architec-
ture and loss of epithelial barrier function observed in
Helicobacter-infected gastric epithelium [86]. MARKs may also
regulate cell polarity by phosphorylating MAPs, for example
tau, and that type of interaction is important for polarized
protein trafficking [87,88].
In neuronal cells, polarization is important for axonal and
dendritic specification that is fundamental to the ability of
neuronal cells to transmit information. LKB1 has been
linked to regulation of polarized migration of neurons and
to promotion of axon initiation during neuronal polarization
through downstream kinases BRSK1 and -2 (also known as
SAD-A and -B), which in turn may contribute to cell polarity
via phosphorylation of MAPs [66,67,89].4. Loss of PAR-4 identity matters in cancer: evil
deeds on the basal side of the epithelial cells
As discussed in the beginning of this review, collapse of a cell
polarity system can benefit cancer progression in multipleways. However, among the pillars of epithelial integrity, the
basement membrane is the last barrier to resist invasion of
motile cancer cells into the neighbouring tissues. Therefore,
any cell-intrinsic or -extrinsic mechanism harming the integrity
or altering the biological activity of basement membrane could
promote invasion and progression to metastatic disease
[24,25,90]. Loss of LKB1 has been shown to influence the
biological activity of basement membrane via non-proteolytic
and proteolysis-dependent mechanisms. The functional inter-
action between LKB1 loss and type II transmembrane
proteases may also involve polarity regulation.
(a) LKB1 and non-proteolytic moulding of basement
membrane
A stiffening of the extracellular matrix, which is attributable to
increased or inappropriate cross-linking of collagens, contrib-
utes to increased migratory and invasive behaviour of cancer
cells and is considered one indicator of poor cancer prognosis
[91–93].One contributing factor tomatrix stiffening is enhanced
activityof lysyl-oxidases (LOX), enzymes that playan important
physiological role in strengthening collagen fibrils, including
type IV collagen of basement membrane, via covalent cross-
linking of lysine residues in these proteins [93]. A functional
role of LOX in cancer has been addressed by blocking LOX
activity, which reduces tumour incidence in the MMTV-Neu
mouse model of breast cancer [93]. Loss-of-function mutations
in LKB1 are common in lung cancer and loss of LKB1 has
been observed to correlate with significantly enhanced levels
of LOX enzymes. In a mouse model of lung cancer and
human non-small cell lung cancer cell lines, loss of LKB1 leads
via enhanced mTOR and HIF1a signalling to enhanced LOX
activity, increaseddeposition of collagen and enhancedprolifer-
ation possibly caused by increased matrix stiffness [94]. Thus,
although the physiological significance of LKB1–LOX crosstalk
remains unclear, loss of LKB1and the consequent dysregulation
of LOX activity in the context of tumour tissue has a prominent
impact onstromal extracellularmatrix remodelling and collagen
biology (figure 3).
(b) LKB1 and proteolytic moulding of basement
membrane
(i) LKB1 and metalloproteinases
Matrix metalloproteinases (MMPs) are a group of enzymes
able to degrade various extracellular matrix and cell surface
molecules, aiding in tissue remodelling and branching mor-
phogenesis. The activity of MMPs is commonly elevated in
cancers [95–97]. However, whether these enzymes specifically
contribute to degradation of collagen IV, a basement mem-
brane transmigration-limiting factor [98], is unclear although
MMP-2 and MMP-9 have been implicated in the process
[95,99]. In a study, LKB1 overexpression has been shown to cor-
relate with downregulation of MMP-2 and MMP-9 and
invasion inhibition in an in vitro assay as well as with the
tumorigenicity and metastasizing capacity of xenografted
tumour cells [100]. However, the significance of these findings
in the context of LKB1 inactivation remains to be determined.
(ii) LKB1 and type II transmembrane serine proteases
In our study, using mice with LKB1-deficient mammary
glands, we found evidence that basement membrane may
mammary epithelial cell
tight
junctions
adherens
junctions
desmosomes
PAR-4/
LKB1
PAR-4/
LKB1
hepsin
hepsin hepsin hepsin
hepsin
LOX
nucleus nucleus
HIF1a
intact BM deteriorated BM increased BM stiffness
breast tumour cell
Figure 3. A model: loss of LKB1 and basement membrane remodelling. Mammary epithelial cells are bound to each other via tight junctions, adhesion junctions
and desmosomes. A TTSP hepsin is expressed on the basal and lateral membranes of epithelial cells, exhibiting a colocalized expression pattern with desmosomes.
Loss of LKB1 inflicts damage to tight junctions and desmosomes, which associate with widespread loss of epithelial integrity. In the present model (modified from
Partanen [32]), this damage liberates hepsin from the membranes into the cytosol. Hepsin is commonly overexpressed in cancer (an effect that can be seen in cells
engineered to overexpress MYC), and we posit that the overexpressed and mislocalized hepsin causes deterioration of basement membrane (BM). Breakdown of BM
is considered an essential step for tumour invasion and metastases. However, loss of LKB1 may also exert opposite, stabilizing effects on BMs and extracellular matrix
by stimulating expression of the collagen cross-linking enzyme LOX [94]. Also, these effects may benefit tumour progression, at least once the tumour has breached
the BM barrier, by increasing the stiffness of the extracellular matrix. Stiff matrix stimulates tumour cell proliferation and, in some instances, migration. The inves-
tigations expose the complex nature of functional interactions between LKB1 and constituents of extracellular matrix, which may inhibit or facilitate tumorigenesis
depending on context.
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7be degraded by type II transmembrane serine proteases
(TTSPs) during mammary tumorigenesis [32]. We reported
that loss of LKB1 does not induce palpable tumours during
the lifetime of the mice but leads to mild abnormalities in the
mammary gland, such as hyperbranching, partial disorganiz-
ation of apical polarity and incomplete basement membrane.
However, combining LKB1 deficiency with oncogenic MYC
dramatically accelerates the appearance of mammary tumours
in comparison with glands exposed to oncogenic MYC alone
[32]. The study shows that both MYCþ and MYCþ;LKB12
tumours are histopathologically mostly adenocarcinomas and
not informative as such regarding the possible mechanisms
underlying accelerated tumorigenesis. However, the histology
of hyperplastic regions in between tumour areas was particu-
larly interesting, providing a path for follow-up studies.
Expression of oncogenic MYC alone, a stimulus known to pro-
mote cell proliferation, had led to development of surplus
ductal branches and alveolar units. All structures generated
under the influence of MYC were separated from stroma and
neighbouring epithelial structures by basement membranes.
By contrast, the hyperplastic regions in the MYCþ;LKB12
mammary glands had surplus epithelial cells but mostly
unrecognizable ductal or alveolar epithelial structures. In the
hyperplastic regions of MYCþ;LKB12 mammary glands, the
bordering basement membranes were missing giving the
impression that epithelial structures were fused together intoa huge disorganized cell mass. Missing basement membrane
was a defining difference between the hyperplastic glands
expressing oncogenic MYC (basement membrane present)
and those expressing MYC combined with loss of LKB1 (base-
ment membrane absent).
Investigating MMECs, isolated from aforementioned mice,
in ex vivo three-dimensional cultures, we observed that MYCþ
epithelial structures were hyperplastic but still maintained
the roundedmorphology. By contrast, theMYCþ;LKB12 struc-
tures showed extensive branching and lacked basement
membrane components, such as nidogen and collagen IV
[32]. A panel of small molecule inhibitors tested in a rescue
assay did not support specific roles for MMPs, but instead
suggested involvement of TTSPs in deterioration of basement
membrane. Subsequent studies identified a strong correlation
between loss of LKB1 and overexpression of a TTSP called
hepsin/TMPRSS1 in our transgenic mouse models and in a
panel of 60 clinical human breast cancer samples. Knock-
down of hepsin rescued basementmembrane inMYCþ;LKB12
three-dimensional structures, indicating a role for hepsin in
basement membrane degradation [32].
While the question of whether, downstream from LKB1
loss, hepsin-mediated deterioration of basement membrane
promotes mammary tumorigenesis has not been addressed,
the oncogenicity of hepsin has been investigated specifically
in prostate cancer models. Hepsin originally caught the
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8attention of cancer researchers in microarray profiling studies,
who found almost ubiquitous overexpression of hepsin in
prostate cancer [101,102]. Nearly 90% of prostate cancers over-
express mRNA for hepsin with up to 30-fold levels compared
with normal prostate tissue. Profound hepsin overexpression
is also found in ovarian and breast cancers, and high hepsin
mRNA levels are commonly accompanied by strong hepsin
protein signal in tumour sections [32,103–106]. A mouse
model engineered to express hepsin under probasin promoter
in prostate has revealed widespread defects in the integrity of
hemidesmosomes and basement membrane, indicating dele-
terious interaction between hepsin overexpression and
basement membrane in vivo [107]. In vitro, the targets for the
proteolytic activity of hepsin include the major basal laminal
component laminin-332 [108]. Basement membrane degra-
dation is a critical step for initiation of cancer metastasis, and
evidence from transgenic and orthotopic tumourgraft models
of prostate and ovarian cancer suggest that overexpression of
hepsin can promote incidence of metastases [104,107,109].
However, the relationship between LKB1-deficiency and
hepsin overexpression in prostate cancer has not yet been
systematically studied. According to the data obtained from
the Wellcome Trust Sanger Institute Cancer Genome
Project web site, http://www.sanger.ac.uk/genetics/CGP
(COSMIC and CONAN), LKB1 mutations have been found
in prostate cancer cell lines and with less than 1% frequency
in prostate cancer but to our knowledge, the epigenetic
influences on gene expression levels have not yet been
addressed in prostate cancer.
(c) Hepsin: permanent desmosome resident or a
cleaver-wielding bandit on the loose
It is still unclear how mechanistically overexpression of
hepsin damages basement membrane, but investigations on
the localization of hepsin in normal and transformed cells,
and changes in this localization in response to oncogenic sig-
nalling may provide some clues. In non-transformed and
some transformed cells, the transmembrane protease hepsin
localizes to cell membranes, its protease domain pointing to
the pericellular space [110]. In ovarian cancer cells and
primary MMEC, the immunostaining pattern of hepsin pro-
minently overlaps with desmosomal proteins [32,104].
Desmosomes are junctional complexes mediating the attach-
ment of specific cell-surface adhesion proteins, desmogleins
and desmocollins, to intracellular intermediate filaments. In
general, tumours express either a membranous or cytosolic
pattern of hepsin depending on the type and grade of the
tumours [32,101,104,105].
Absence of critical desmosomal proteins, for instance des-
moplakin, or depletion of desmoplakin in response to LKB1
inactivation leads to translocation of hepsin from cell–cell bor-
ders to cytosol [32,104]. In ovarian cancer cells, also, the
ectopically overexpressed hepsin is mainly cytosolic [104].
Therefore, it can be hypothesized that hepsin is normally
sequestered to desmosomes but if the junctional integrity is
compromised, as inmost cancer cells, hepsin becomes liberated
in the cytosol (figure 3). It still remains amystery how cytosolic
hepsin interacts with basement membrane but it is interesting
to note that vesicular trafficking plays an important role in the
activation cascades of other TTSPs. A TTSP family member,
matriptase has been reported to activate a downstream TTSP
prostasin on the basolateral membrane of polarized colonicepithelial cells fromwhich activated prostasin is intracellularly
transcytosed to apical membrane of the cells [111]. It is tempt-
ing to speculate that loss of cues for directional secretion in
depolarized cancer cells perturbs cell polarity-coupled proteo-
lytic cascades. Hence, disruption of polarity could lead to
uncontrolled proteolytic attacks on different cellular domains,
including basement membranes.
Finally, in addition to causing physical damage to basement
membrane, overexpressed (or liberated) hepsin may also con-
tribute to tumour progression via remodelling of basement
membrane, which is not only a barrier but also a dynamic scaf-
fold that controls access of the cells to various growth factors.
For example, proteoglycans bind and sequester growth factors
and cytokines, regulating their availability to cells [112,113].
Moreover, basement membrane proteins often contain cryptic
sites, which are exposed after extracellular matrix digestion
and can consequently act as pro-migratory, pro-invasive or
angiogenic cues [2,114]. Hepsin can proteolytically activate
many factors in themicroenvironment of epithelial cells, includ-
ing hepatocyte growth factor, urokinase-type plasminogen
activator, macrophage-stimulating protein and EGF receptor,
all of which are well-known players in cancer [110,115–120].5. Conclusion: lessons learned and
challenges ahead
Common interest in regulation and dysregulation of cell
polarity in health and disease has recently brought together
biologists with diverse backgrounds, representing single cell
and invertebrate models, developmental and neurobiology,
and cancer biology. In particular, past studies in Drosophila,
revealing how potently loss-of-gene functions involved in
cell polarity and epithelial integrity promote tumorigenesis,
have spurred interest in the polarity pathways among
cancer biologists. However, it is clear that the evolutionary
distance and gene diversification between flies and humans
makes it challenging to directly relate tumour genetics in
flies to human cancer. For example, it is still a matter of
debate whether the closest human structural homologues of
fly nTSGs are prevalent in human tumour suppressor
genes. While the ongoing studies on human versions of
nTSGs are expected to shed light on the question, it is also
emerging that the PAR clan of proteins plays an important
role at the intersection of polarity regulation and tumour sup-
pression in mammals. PAR-4/LKB1 is the clan member with
a strongest link to cancer but the multiple functions of LKB1
makes it challenging to discern the role of the PAR-4 identity
of LKB1 in tumorigenesis. PAR-4 also does not have asym-
metric localization in cells, in contrast to for example apical
PAR-3 and PAR-6, which makes it difficult to distinguish
between apical and basal polarity-directed actions of PAR-
4/LKB1. However, current studies have indicated evidence
that loss of PAR-4/LKB1 weakens apical cell–cell cohesion
and launches hepsin-mediated proteolytic and LOX invol-
ving non-proteolytic pathways to digest and remodel the
basement membrane on the basal side of the cells as well
as extracellular matrix—all of these events promote the
spread of cancer cells from epithelial structures to connective
tissue. While this evidence supports the involvement of the
PAR-4 identity in tumour development, a strong case also
exists to convict the LKB1-AMPK-mTOR branch of involve-
ment in tumorigenesis. On which side does the burden of
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9proof lie? According to current knowledge, LKB1 predomi-
nantly signals via AMPK and the PAR-4 identity of LKB1
signals via activation of PAR1 (MARKs). However, how sep-
arate these identities in fact are is a question that will deserve
closer inspection. PAR-1/MARK proteins belong to a family
of ARKs and, in addition, evidence exists from studies in flies
and mammals indicating the involvement of LKB1-AMPK
axis in polarity regulation. The possibility that metabolic
pathways interact with polarity pathways, or vice versa, war-
rants further studies as an area of obvious interest and
significance to epithelial biology. This takes us back to Ste-
venson’s novella, The Strange Case of Dr Jekyll and Mr Hyde.
At the end of the story, the line between the different identi-
ties of Dr Jekyll and Mr Hyde becomes blurred when Dr
Jekyll keeps metamorphosing into Hyde involuntarily and
Hyde seeks a potion to revert back to Dr Jekyll again. Ifthis chapter holds to the strange case of LKB1/PAR-4,
future research will identify not only isolated phenotypes
attributed to LKB1/PAR-4 but also signalling nodes linking
different LKB1/PAR-4 regulated networks and cellular phe-
notypes. Such nodes would be prime targets for therapeutic
potions aiming to change evil Hyde back to Jekyll again.
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